Pfizer: PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo
The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.
Read full article »
Pfizer is a New York-based pharmaceutical company that develops and commercializes medicines and vaccines for the healthcare industry.
Read more